R. Lamy

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016 · 969 citations · Full text

Advanced Lung Disease, Medicine, Pathology +8

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

R. Corre, Laurent Greillier, H. Le Caer et al. · Journal of Clinical Oncology · 2016 · 401 citations

Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

Florian Guisier, Catherine Dubos‐Arvis, F. Viñas et al. · Journal of Thoracic Oncology · 2020 · 287 citations · Full text

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Anthony Gonçalvès, Marine Gilabert, E. François et al. · Annals of Oncology · 2012 · 213 citations · Full text

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +9

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Nathalie Baize, I. Monnet, Laurent Greillier et al. · The Lancet Oncology · 2020 · 145 citations

Second-line Treatment, Medicine, Pathology +7